The Company has a rich and diversified pipeline of preclinical assets balanced around its three strategic pillars: checkpoint inhibition, tumor microenvironment targeting and tumor antigen targeting but also on different antibody formats.
AstraZeneca selected four molecules from Innate’s preclinical portfolio per the October 23, 2018 transaction terms. Selected molecules include the anti-MICA/B antibody drug conjugate* (IPH43) and the anti-Siglec 9 antibody program. Two other programs are undisclosed and include a multi-specific NKp46 NK cell engager.
* In 4Q 2018, the Company elected to advance the anti-MICA/B program as an ADC-antibody and terminated the naked antibody (ADCC) program IPH4301.